Three Months Ended June 30, 2022 (2021) Six Months Ended June 30, 2022 (2021) Revenue was SEK 3.0 M (1.9 M) Revenue was SEK 9.6 M (5.3 M) Operating profit/loss was SEK -91.8 M (-103.6 M) Net profit/loss was SEK -88.6 M (-103.9 M) Operating profit/loss was SEK -225.0 M (-197.7 M) Net profit/loss was

PRESS RELEASE August 18 , 202 2 Today, on August 18 , 2022, an extraordinary general meeting was held in Saniona AB . A summary of the adopted resolution follows below. The resolution w as adopted with the required majority of vot es. Resolution on (A) employee option program ; and (B) directed

PRESS RELEASE August 16 , 202 2 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that it ha s progressed its promising Kv7 epilepsy program into the Lead Optimization Phase , which is the last drug discovery phase before potential selection of a clinical candidat

PRESS RELEASE August 5 , 202 2 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that 6,45 0, 734 options have forfeited in 20 22, leading to a reduction in potential dilution from 11.89% to 3.0 6 %. As of December 31, 2021, the company had 8,402,181 options

PRESS RELEASE 15 July 202 2 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders in Saniona AB, Reg. No. 556962-5345, are hereby invited to attend the extraordinary general

PRESS RELEASE Ju ly 6 , 202 2 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that the CEO and a member of the B oard of Directors have purchased 2 4 0 ,221 shares of the company in the open market for a total value of approximately SEK 0 . 9 million .

PRESS RELEASE June 30 , 202 2 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that it has successfully completed its Phase 1 clinical trial of SAN711 , which is positioned for the treatment of neuropathic pain disorders.

PRESS RELEASE June 24 , 202 2 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that professor Helle Prætorius , Univ. of Aarhus, Denmark, made a presentation at the ECM conference , 2022 , which shows that SAN903 protect s against fibrosis in a chronic kindney

PRESS RELEASE May 25 , 202 2 Today, on May 25 , 2022, the annual shareholders’ meeting was held in Saniona AB . T he annual shareholders’ meeting was held only by advance voting (postal vote) in accordance with temporary legislation . A summary of the adopted resolutions follows below.

  Q1 2022 ( Q1 2021 ) Revenue was SEK 6.6 M (3.4 M) Operating loss was SEK -133.2 M (-94.1 M) Net loss was SEK -133.4 M (-83.4 M) Loss per share was SEK -2.14 (-1.34) Diluted loss per share was SEK -2.14 (-1.34) Business highlights in Q1 2022 Saniona initiated the Multiple Ascending Dose (MAD)